Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma

Blood Adv. 2023 Jun 13;7(11):2494-2495. doi: 10.1182/bloodadvances.2022009469.

Authors

John Gribben¹, M Lia Palomba², Anik R Patel³, Myrna Nahas³, Sattva S Neelapu⁴

Affiliations

¹ Barts Cancer Institute, Queen Mary University of London, United Kingdom.
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Kite, A Gilead Company, Santa Monica, CA.
⁴ The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Cost-Benefit Analysis
Humans
Lymphoma, Follicular*
Risk Adjustment
Rituximab

Substances

Rituximab
Antibodies, Monoclonal, Murine-Derived